Proactive Investors - Run By Investors For Investors

Boston Scientific rises as preliminary 4Q sales figures match consensus estimate

For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion
A surgeon putting on gloves
For all of 2018, Boston Scientific reported a 8.6% gain in preliminary sales

Boston Scientific Corp (NYSE:BSX) advanced Tuesday after reporting preliminary fourth-quarter sales figures that were in line with the consensus estimate.

The Marlborough, Massachusetts-based medical products company said preliminary sales increased 6.3% on a reported based during the fourth quarter to $2.56 billion. That matched the average estimate of analysts.

READ: Johnson & Johnson third-quarter results beat estimates; raises guidance for 2018

Shares of Boston Scientific rose $0.47, or 1.4%, to $34.89 in New York Stock Exchange trading.
 
For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion.

Highlights included a 10.9% gain in its urology and pelvic health segment and 6.4% growth in its cardiovascular business.

Contact Dennis Fitzgerald at [email protected]

View full BSX profile View Profile

Boston Scientific Timeline

Related Articles

researcher
April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline
Pictured is the company's myLotus test
May 15 2019
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
Sativa
June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use